This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Avanir Pharmaceuticals, Inc. (AVNR)
F2Q2012 Earnings Conference Call
May 08, 2012, 09:00 a.m. ET
Ian Clements - Senior Director, IR
Keith Katkin - President and CEO
Rohan Palekar - SVP and CCO
Christine Ocampo - VP, Finance
Joao Siffert - SVP, Research and Development
Randall Kaye - SVP, Medical Affairs and Chief Medical Officer
Roy - JMP Securities
Ritu Baral - Canaccord Adams
Greg Wade - Wedbush Pac Grow Life Sciences
Thomas Wei - Jefferies
George Zavoico - MLV and Company
Good day ladies and gentlemen and welcome to the Second Quarter 2012 Avanir Pharmaceuticals Earnings Conference Call. My name is Pam and I will be your operator for today. At this time all participants are in listen-only mode, later we will conduct a question-and-answer session. (Operator Instructions) As a reminder this conference is being recorded for replay purposes.
I’d now like to turn the conference over to Mr. Ian Clements, Senior Director of Investor Relations. Please proceed.
Thanks Pam. Good morning everybody. I’d like to welcome you to our conference call to discuss our financial and operating results for the fiscal 2012 second quarter.
To discuss our results I’m joined by Keith Katkin, our President and Chief Executive Officer, who will provide a strategic overview of our business and fiscal 2012 second quarter performance; Christine Ocampo, our Vice President of Finance who will provide additional details on our financial performance during the quarter; Rohan Palekar, our Chief Commercial Officer; and Joao Siffert, Senior Vice President, Research and Development, who will provide an R&D update. For the Q&A portion of today’s call we will also be joined by Dr. Randall Kaye, our Chief Medical Officer.